24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Tired, Anxious, Overweight: How Lockdowns May Have Harmed Your HealthEli Lilly Antibody Drug Could Prevent COVID Hospitalizations: StudyDeath Rates Are Dropping for New Yorkers With COVID-19 -- Why?Asymptomatic Kids With COVID-19 May Also Carry Less VirusYour Guide to Getting a COVID-19 TestFauci Calls for National Mask MandateSmog Could Increase COVID-19 Deaths by 15% WorldwidePatients With Worst COVID-19 May Be Best Plasma Donors: StudyWill Expelled Droplets Spread COVID? Ventilation May Be KeyPeople With Down Syndrome Face Higher Risk of Severe COVID-19Loss of Smell More Common in COVID-19 Than ThoughtPsoriasis Meds Don't Raise Risk of Severe COVID-19: StudyTrial of Antibody Drug for COVID-19 Stopped for Lack of EffectivenessKnee or Hip Replacements Cut People's Risk for Falls: StudyWhat Will It Take for People to Embrace a COVID Vaccine?Kidney Trouble Greatly Raises Odds for Fatal COVID-19More Evidence Masks Slow COVID's SpreadDangerous COVID-19 Syndrome First Seen in Kids Also Strikes AdultsFading Sense of Smell Could Signal Higher Death Risk in Older AdultsHospitals Straining Under Weight of Surging COVID Case CountsU.S. Daily COVID-19 Case Count Sets New Record for the PandemicAn Unexpected Finding on What Might Drive Joint DiseaseCoronavirus in a Cough: Tests Show Masks Stopping the SpreadU.S. Daily COVID Case Count Nears Record for PandemicCould Common Asthma Meds Weaken Bones?Mask Use by Americans Now Tops 90%, Poll FindsCOVID-19 More Common in Pregnant Hispanics Than Other Moms-to-Be: StudyMore Than Half of Americans Know Someone Infected or Ill With COVID: PollCDC Broadens Definition of 'Close Contact' in Tracing COVID InfectionsAHA News: The Mummies' Message: Take Steps Against Heart DiseasePancreas Cells That Drive Type 1 Diabetes Appear in Healthy People, TooOne Big Reason Women May Be Less Prone to COVID-19New Wave of COVID Infections Taking Hold in AmericaSmog Tied to Raised Risk for Parkinson's, Alzheimer's DiseaseWhat Will Convince Americans to Get a COVID-19 Vaccine?Curbing COVID Brought Unexpected Benefit for Asthma Patients1 in 3 Americans With Arthritis Say Pain, Symptoms PersistCDC Recommends Face Masks in All Public Transportation SettingsIn Medieval Times, Plagues 'Sped Up' With Each New OutbreakWhat You Need to Know About Your Colon Cancer RiskNewer Rheumatoid Arthritis Drug May Help Ease Tough-to-Treat CasesCelebrate Autumn Traditions Without Raising Your COVID RiskNew Drug Could Extend Life for People With ALSHeart Defects Don't Increase Risk of Severe COVID-19Chinese COVID Vaccine Shows Promise in Early TrialAmerica Sees Daily COVID Cases Pass 60,000 Once AgainCOVID Scored Big at 'Superspreader' Hockey GameAHA News: Belly Fat May Signal Early Heart Issues for Mexican AmericansFDA Approves First Ebola Virus TreatmentAmericans Might Need to Pass on Thanksgiving Gatherings: Fauci
Questions and AnswersLinks
Related Topics

Diabetes

Probiotic Might Help Ease Children's Eczema

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Sep 15th 2020

new article illustration

TUESDAY, Sept. 15, 2020 (HealthDay News) -- Applying a type of "good" bacteria to the skin may relieve children of the itch and discomfort of eczema, a new, small study suggests.

Eczema is a chronic inflammatory condition that causes dry, itchy skin and scaly rashes. It usually starts in early childhood, and commonly occurs along with allergies like hay fever and asthma, according to the American Academy of Allergy, Asthma and Immunology.

There are numerous treatments for eczema, both topical and oral, but not all can be given to young kids.

"So, there's a big need for safe and effective treatments for young children," said study author Dr. Ian Myles. He is a researcher and staff clinician with the U.S. National Institute of Allergy and Infectious Diseases.

For the study, his team tested a topical probiotic against eczema in 20 children as young as 3 years of age. Over four months, 17 of the 20 saw their rashes and itchiness fade by more than 50%.

The children were also able to cut down on topical corticosteroids, a standard treatment for eczema -- but one that can cause side effects like thinning of the skin and stretch marks.

The probiotic therapy is a spray solution containing live Roseomonas mucosa bacteria. Those microbes are normally present on the skin, and past research has found that R. mucosa from people with healthy skin can treat eczema in lab mice.

In contrast, samples of the bacteria from people with eczema either had no effect, or made the skin condition worse.

It all fits with evidence that eczema involves an imbalance in the skin's microbiome. That refers to the vast array of bacteria and other microbes that naturally dwell on the skin and help maintain its health.

The skin, Myles explained, has to repair itself from daily wear-and-tear, and the microbiome assists in that. He said R. mucosa appears to produce oils that aid the skin's repair capacity.

The treatment also reduced staph bacteria on the children's skin, and those microbes can worsen eczema symptoms.

Dr. John Browning, a pediatric dermatologist, said, "I think this is a really interesting study." Browning was not involved in the research.

He said people with eczema often get staph infections and need antibiotic treatment. It's possible R. mucosa could be an alternative, according to Browning, who is based at Children's Hospital of San Antonio and Texas Dermatology and Laser Specialists.

The findings, published online Sept. 9 in the journal Science Translational Medicine, are based on 20 children and teenagers who were given the probiotic therapy for four months. They (or their parents) applied the spray solution twice a week for three months, and then every other day for the final month.

On average, Myles said, the kids' itchiness and rash improved by 60% to 75%, with no significant side effects.

And there were signs it could have lasting benefits. Eight months after the therapy was stopped, the good bacteria were still colonizing the children's skin -- indicating R. mucosa had "moved in," Myles explained.

That, he said, suggests the therapy could be one time only. It would still be possible, though, that whatever caused the bacterial imbalance in the skin could do it again.

Myles said a broader goal is to figure out what those factors are -- with diet, soaps and antibiotics being among the suspects.

Browning is part of another trial testing R. mucosa for treating eczema. But he does not think it is the only bacterium that matters.

"There could be a lot of variability patient to patient in whether this approach would be helpful," Browning said.

Myles agreed, noting that not all study patients responded to the probiotic.

It's unclear when the R. mucosa therapy could become commercially available. The U.S. National Institutes of Health has licensed it to a private company, Forte Biosciences, to further develop.

Myles said the company worked to freeze-dry the probiotic so it can be reconstituted with water, then sprayed on. That will make it shelf-stable.

"We anticipate this being something you can pick up at the pharmacy," he said.

More information

The American Academy of Allergy, Asthma and Immunology has more on eczema.